CA3137901A1 - Heterocyclic inhibitors of tyrosine kinase - Google Patents
Heterocyclic inhibitors of tyrosine kinase Download PDFInfo
- Publication number
- CA3137901A1 CA3137901A1 CA3137901A CA3137901A CA3137901A1 CA 3137901 A1 CA3137901 A1 CA 3137901A1 CA 3137901 A CA3137901 A CA 3137901A CA 3137901 A CA3137901 A CA 3137901A CA 3137901 A1 CA3137901 A1 CA 3137901A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- recited
- egfr
- chosen
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838696P | 2019-04-25 | 2019-04-25 | |
| US62/838,696 | 2019-04-25 | ||
| PCT/US2020/029849 WO2020219904A1 (en) | 2019-04-25 | 2020-04-24 | Heterocyclic inhibitors of tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3137901A1 true CA3137901A1 (en) | 2020-10-29 |
Family
ID=72941423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3137901A Pending CA3137901A1 (en) | 2019-04-25 | 2020-04-24 | Heterocyclic inhibitors of tyrosine kinase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11365189B2 (https=) |
| EP (1) | EP3962908A4 (https=) |
| JP (1) | JP7601788B2 (https=) |
| CN (2) | CN118852118A (https=) |
| AU (1) | AU2020261423B2 (https=) |
| CA (1) | CA3137901A1 (https=) |
| WO (1) | WO2020219904A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| US20240246940A1 (en) * | 2021-04-22 | 2024-07-25 | Voronoi Inc. | Heteroaryl derivative compound and use thereof |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
| WO2022266425A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 3-cyano-quinoline derivatives and uses thereof |
| JP2024532249A (ja) * | 2021-08-24 | 2024-09-05 | アースローシ セラピューティクス，インク． | 疾患の処置のためのキナゾリン化合物 |
| CN115894486B (zh) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476008C (en) * | 2002-03-30 | 2011-12-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| WO2015154725A1 (zh) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
| JP6704422B2 (ja) * | 2015-03-20 | 2020-06-03 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | キナゾリン誘導体の塩およびその製造方法 |
| JP7036798B2 (ja) * | 2016-08-25 | 2022-03-15 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | キナゾリン誘導体の塩の結晶 |
| WO2019165003A1 (en) * | 2018-02-20 | 2019-08-29 | Dawei Zhang | Substituted quinolines useful as kinase inhibitors |
| EP3962908A4 (en) | 2019-04-25 | 2022-10-26 | Board of Regents, The University of Texas System | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE |
-
2020
- 2020-04-24 EP EP20796402.4A patent/EP3962908A4/en active Pending
- 2020-04-24 CA CA3137901A patent/CA3137901A1/en active Pending
- 2020-04-24 JP JP2021563139A patent/JP7601788B2/ja active Active
- 2020-04-24 CN CN202410871766.0A patent/CN118852118A/zh active Pending
- 2020-04-24 CN CN202080045535.4A patent/CN114026083B/zh active Active
- 2020-04-24 US US16/858,116 patent/US11365189B2/en active Active
- 2020-04-24 WO PCT/US2020/029849 patent/WO2020219904A1/en not_active Ceased
- 2020-04-24 AU AU2020261423A patent/AU2020261423B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026083A (zh) | 2022-02-08 |
| JP2022529518A (ja) | 2022-06-22 |
| CN118852118A (zh) | 2024-10-29 |
| US11365189B2 (en) | 2022-06-21 |
| AU2020261423A1 (en) | 2021-12-09 |
| CN114026083B (zh) | 2024-07-09 |
| AU2020261423B2 (en) | 2026-01-29 |
| EP3962908A4 (en) | 2022-10-26 |
| JP7601788B2 (ja) | 2024-12-17 |
| WO2020219904A1 (en) | 2020-10-29 |
| US20200354343A1 (en) | 2020-11-12 |
| EP3962908A1 (en) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020261423B2 (en) | Heterocyclic inhibitors of tyrosine kinase | |
| EP3833670B1 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| US11690850B2 (en) | Inhibitors of receptor interacting protein kinase I for the treatment of disease | |
| WO2020033955A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| CA3024706A1 (en) | Heterocyclic inhibitors of ptpn11 | |
| US11713313B2 (en) | GLS1 inhibitors for treating disease | |
| US12559497B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| WO2020219906A1 (en) | Heterocyclic inhibitors of tyrosine kinase | |
| US12540139B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| WO2018213777A1 (en) | Heterocyclic inhibitors of kdm5 for the treatment of disease | |
| CA3009355C (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide | |
| HK40015139B (en) | Heterocyclic inhibitors of mct4 | |
| HK40015139A (en) | Heterocyclic inhibitors of mct4 | |
| CA3009355A1 (en) | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240423 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251210 |